.svg){kind=small}
.png)
In November 2020, Richmond Pharmacology made medical history when a patient received the first-ever systemically delivered CRISPR therapy, using lipid nanoparticles to edit genes directly inside the human body. This marked the beginning of the Nex-Z clinical trial with Intellia Therapeutics, ushering in a new era of in vivo gene editing.
Two of the earliest participants, Ann Deegan and James Green, spoke about the impact of their treatment at London Life Sciences Week in November 2025, appearing alongside Dr Jörg Taubel, Richmond’s CEO and founder.
Transforming the outlook for hereditary amyloidosis
ATTR amyloidosis occurs when a faulty gene causes misfolded TTR proteins to accumulate in organs. Nex-Z uses CRISPR-Cas9 “genetic scissors” to cut the defective gene, stopping production of the harmful protein.
Since receiving treatment, Ann and James, who later co-founded Amyloidosis Ireland, have seen dramatic health improvements.
Ann Deegan:
“I’ve been so well since. If sharing my experience helps someone recognise the signs early or feel hope for the future, it’s worth it.”
James Green:
“Being part of the CRISPR trial has been life-changing. It’s transformed my health and given hope to families facing this disease.”
Five years of pioneering progress
Since the landmark first infusion, over 200 patients have received in vivo gene-editing therapies at Richmond’s London facilities, more than at any other site worldwide. Richmond has partnered with leading innovators including Intellia, Beam, Verve, CRISPR Therapeutics, and Regeneron.
Recent global data, including promising results from Verve-102 for high cholesterol, highlight the accelerating potential of one-time genetic medicines.
Dr Jörg Taubel:
“On 5 November 2020, CRISPR-Cas9 gene editing was administered by systemic infusion for the first time — under my supervision at Richmond. Since then, we’ve dosed more patients with in vivo gene-editing and base-editing therapies than any other centre in the world. We remain proud to turn revolutionary science into real hope.”
This article was published here.
Read more here:
Donegal News, Donegal Daily, Irish Medical Times
.avif)
